FDA grants fasttrack designation to bone marrow cancer drug

FDA grants fast-track designation to bone marrow cancer drug

19:00 EDT 6 Jun 2019 | Pharmaceutical Technology

Sierra Oncology has received the US Food and Drug Administration’s (FDA) fast track designation for its investigational drug momelotinib. Indicated...
Read More...

The post FDA grants fast-track designation to bone marrow cancer drug appeared first on Pharmaceutical Technology.

Original Article: FDA grants fast-track designation to bone marrow cancer drug

More From BioPortfolio on "FDA grants fast-track designation to bone marrow cancer drug"